Venetoclax (Venclexta) kanye rituximab (Rituxan) zisetshenziswa ngokuhambisana nokubuyela emuva / i-refractory chronic lymphocytic leukemia ( Cll ), okuholela ezingeni eliphezulu lesifo esiyinsalela ( uMRD ), Ehlotshaniswa nokusinda okungenayo inqubekela phambili isikhathi eside ( I-PFS ).
Iziguli eziphethwe iVenetoclax kanye ne-rituximab zazinezikhathi eziphindwe ka-5 zesimo se-uMRD uma zihlanganiswa ne-phenytoin ne-rituximab, futhi inani leziguli ezigcine lesi simo ezinyangeni ezingama-24 laliphezulu eqenjini le-venetoclax / rituximab izikhathi ezingama-20 noma ngaphezulu. Uma kuqhathaniswa nesimo se-MRD, i-uMRD yayihlotshaniswa nokwehliswa kwama-62% engcupheni yokuqhubekela phambili kwezifo noma ukufa.
The MRD status has been proven to predict PFS in CLL patients treated with chemoimmunotherapy , but the predictive value of MRD for new drugs remains uncertain. Data from the random MURANO trial provides an opportunity to examine the predictive value of MRD and CLL without chemotherapy.
I-MURANO yisivivinyo sesigaba III esingahleliwe esihlola ukusebenza kwe-rituximab kuhlanganiswe ne-venetoclax kuqhathaniswa ne-bendamustine ezigulini ezingama-389 ezine-CLL ebuyile / ephikisayo. Isiguli sithole iminyaka engu-2 ye-venetoclax nezinyanga zokuqala eziyi-6 ze-rituximab, noma izinyanga eziyisithupha ze-bendamustine kanye ne-rituximab izinyanga eziyisithupha.
Ukuhlaziywa kokuqala kukhombisile ukuthi uma kuqhathaniswa ne-rituximab ne-bendamustine, ubungozi bokuqhubeka kwesifo noma ukufa kwaba yi-84% eminyakeni engu-3 yokwelashwa nge-venetoclax ne-rituximab.
